Advances in PET/CT Imaging for Breast Cancer Patients and Beyond—Volume II
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nuclear Medicine & Radiology".
Deadline for manuscript submissions: 25 July 2024 | Viewed by 94
Special Issue Editors
2. Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France
Interests: PET/CT imaging; new tracers; breast cancer; prognostic/predictive biomarkers; precision medicine
Special Issues, Collections and Topics in MDPI journals
Interests: artificial intelligence; radiomics; immunotherapy
Special Issues, Collections and Topics in MDPI journals
2. LTSI (Laboratoire Traitement du Signal et de l'Image), Université de Rennes 1, 35042 Rennes, France
Interests: medical imaging; nuclear medicine; lobular breast cancer; brain metastases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Over the last decade, molecular imaging has remarkably improved the management of patients with breast cancer. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is now a cornerstone for in vivo characterization and measurement of biologic processes, with several clinical applications, such as staging and assessment of treatment response. Moreover, innovative PET radiotracers present novel clinical opportunities, such as the selection of patients for endocrine therapy, anti-HER2 therapy, and immunotherapy. For patients with metastatic breast cancer, 18F-fluoroestradiol (FES) is a promising tracer that can be used for a whole-body assessment of estrogen receptor status. The fibroblast activation protein inhibitor (FAPI), labeled with Gallium-68 or Fluor-18, is also under investigation, with encouraging results. Thus, several research teams have recently studied FAPIs’ potential to compete with or even outperform FDG in a number of clinical indications, including diagnosis/staging, treatment response assessment, radiotherapy planning, and theranostics. For this Special Issue, we encourage the submission of papers considering innovative approaches using PET/CT imaging to guide the management of patients with a diagnosis of breast cancer.
Dr. Romain David Seban
Dr. Laurent Dercle
Dr. Antoine Girard
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- PET/CT imaging
- fluorodeoxyglucose (FDG)
- fluoroestradiol (FES)
- tracers targeting fibroblast activation protein inhibitors (FAPIs)
